{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:39:00Z","timestamp":1790768340136,"version":"4.1.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T00:00:00Z","timestamp":1502668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T00:00:00Z","timestamp":1502668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Leukemia cells rely on two nucleotide biosynthetic pathways, de novo and salvage, to produce dNTPs for DNA replication. Here, using metabolomic, proteomic, and phosphoproteomic approaches, we show that inhibition of the replication stress sensing kinase ataxia telangiectasia and Rad3-related protein (ATR) reduces the output of both de novo and salvage pathways by regulating the activity of their respective rate-limiting enzymes, ribonucleotide reductase (RNR) and deoxycytidine kinase (dCK), via distinct molecular mechanisms. Quantification of nucleotide biosynthesis in ATR-inhibited acute lymphoblastic leukemia (ALL) cells reveals substantial remaining de novo and salvage activities, and could not eliminate the disease in vivo. However, targeting these remaining activities with RNR and dCK inhibitors triggers lethal replication stress in vitro and long-term disease-free survival in mice with B-ALL, without detectable toxicity. Thus the functional interplay between alternative nucleotide biosynthetic routes and ATR provides therapeutic opportunities in leukemia and potentially other cancers.<\/jats:p>","DOI":"10.1038\/s41467-017-00221-3","type":"journal-article","created":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T20:37:02Z","timestamp":1501879022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways"],"prefix":"10.1038","volume":"8","author":[{"given":"Thuc M.","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Poddar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Capri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan R.","family":"Abt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woosuk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhu T.","family":"Uong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe M.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Braas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Nikanjam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Merkurjev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Zaretsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harley I.","family":"Kornblum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey R.","family":"Herschman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Whitelegge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kym F.","family":"Faull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Czernin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9338-5397","authenticated-orcid":false,"given":"Caius G.","family":"Radu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,14]]},"reference":[{"key":"221_CR1","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1093\/nar\/gkq128","volume":"38","author":"D Kumar","year":"2010","unstructured":"Kumar, D., Viberg, J., Nilsson, A. K. & Chabes, A. Highly mutagenic and severely imbalanced dNTP pools can escape detection by the S-phase checkpoint. Nucleic Acids Res. \n                           38, 3975\u20133983 (2010).","journal-title":"Nucleic Acids Res."},{"key":"221_CR2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1146\/annurev.bi.57.070188.002025","volume":"57","author":"P Reichard","year":"1988","unstructured":"Reichard, P. Interactions between deoxyribonucleotide and DNA synthesis. Annu. Rev. Biochem. \n                           57, 349\u2013374 (1988).","journal-title":"Annu. Rev. Biochem."},{"key":"221_CR3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1146\/annurev.biochem.75.103004.142443","volume":"75","author":"P Nordlund","year":"2006","unstructured":"Nordlund, P. & Reichard, P. Ribonucleotide reductases. Annu. Rev. Biochem. \n                           75, 681\u2013706 (2006).","journal-title":"Annu. Rev. Biochem."},{"key":"221_CR4","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1038\/onc.2014.155","volume":"34","author":"Y Aye","year":"2015","unstructured":"Aye, Y., Li, M., Long, M. J. & Weiss, R. S. Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. Oncogene \n                           34, 2011\u20132021 (2015).","journal-title":"Oncogene"},{"key":"221_CR5","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jmb.2008.02.061","volume":"378","author":"E Sabini","year":"2008","unstructured":"Sabini, E., Hazra, S., Ort, S., Konrad, M. & Lavie, A. Structural basis for substrate promiscuity of dCK. J. Mol. Biol. \n                           378, 607\u2013621 (2008).","journal-title":"J. Mol. Biol."},{"key":"221_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrc2817","volume":"10","author":"DA Tennant","year":"2010","unstructured":"Tennant, D. A., Dur\u00e1n, R. V. & Gottlieb, E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer \n                           10, 267\u2013277 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"221_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature \n                           483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"221_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nmeth.3692","volume":"13","author":"J Fernandez-Banet","year":"2016","unstructured":"Fernandez-Banet, J. et al. OASIS: web-based platform for exploring cancer multi-omics data. Nat. Methods \n                           13, 9\u201310 (2016).","journal-title":"Nat. Methods"},{"key":"221_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. \n                           2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"221_CR10","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. \n                           6, pl1 (2013).","journal-title":"Sci. Signal."},{"key":"221_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/ncb3124","volume":"17","author":"LK Boroughs","year":"2015","unstructured":"Boroughs, L. K. & DeBerardinis, R. J. Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. \n                           17, 351\u2013359 (2015).","journal-title":"Nat. Cell Biol."},{"key":"221_CR12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20131738","volume":"211","author":"DA Nathanson","year":"2014","unstructured":"Nathanson, D. A. et al. Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication. J. Exp. Med. \n                           211, 473\u2013486 (2014).","journal-title":"J. Exp. Med."},{"key":"221_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","volume":"136","author":"J Luo","year":"2009","unstructured":"Luo, J., Solimini, N. L. & Elledge, S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell \n                           136, 823\u2013837 (2009).","journal-title":"Cell"},{"key":"221_CR14","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1084\/jem.20121061","volume":"209","author":"WR Austin","year":"2012","unstructured":"Austin, W. R. et al. Nucleoside salvage pathway kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress. J. Exp. Med. \n                           209, 2215\u20132228 (2012).","journal-title":"J. Exp. Med."},{"key":"221_CR15","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.1073\/pnas.0913900107","volume":"107","author":"G Toy","year":"2010","unstructured":"Toy, G. et al. Requirement for deoxycytidine kinase in T and B lymphocyte development. Proc. Natl Acad. Sci. USA \n                           107, 5551\u20135556 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"221_CR16","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1126\/science.1228792","volume":"339","author":"I Ben-Sahra","year":"2013","unstructured":"Ben-Sahra, I., Howell, J. J., Asara, J. M. & Manning, B. D. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science \n                           339, 1323\u20131328 (2013).","journal-title":"Science"},{"key":"221_CR17","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1126\/science.1228771","volume":"339","author":"AM Robitaille","year":"2013","unstructured":"Robitaille, A. M. et al. Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science \n                           339, 1320\u20131323 (2013).","journal-title":"Science"},{"key":"221_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.molcel.2014.05.028","volume":"55","author":"A Saha","year":"2014","unstructured":"Saha, A. et al. Akt phosphorylation and regulation of transketolase is a nodal point for amino acid control of purine synthesis. Mol. Cell \n                           55, 264\u2013276 (2014).","journal-title":"Mol. Cell"},{"key":"221_CR19","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cell.2014.03.052","volume":"157","author":"JT Cunningham","year":"2014","unstructured":"Cunningham, J. T., Moreno, M. V., Lodi, A., Ronen, S. M. & Ruggero, D. Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer. Cell \n                           157, 1088\u20131103 (2014).","journal-title":"Cell"},{"key":"221_CR20","doi-asserted-by":"publisher","first-page":"e2722","DOI":"10.1371\/journal.pone.0002722","volume":"3","author":"YC Liu","year":"2008","unstructured":"Liu, Y. C. et al. Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS. ONE. \n                           3, e2722 (2008).","journal-title":"PLoS. ONE."},{"key":"221_CR21","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.celrep.2013.03.004","volume":"3","author":"KM Aird","year":"2013","unstructured":"Aird, K. M. et al. Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep. \n                           3, 1252\u20131265 (2013).","journal-title":"Cell Rep."},{"key":"221_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nrd4553","volume":"14","author":"M Dobbelstein","year":"2015","unstructured":"Dobbelstein, M. & S\u00f8rensen, C. S. Exploiting replicative stress to treat cancer. Nat. Rev. Drug. Discov. \n                           14, 405\u2013423 (2015).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"221_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","volume":"149","author":"AM Weber","year":"2015","unstructured":"Weber, A. M. & Ryan, A. J. ATM and ATR as therapeutic targets in cancer. Pharmacol. Ther. \n                           149, 124\u2013138 (2015).","journal-title":"Pharmacol. Ther."},{"key":"221_CR24","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/nrm2852","volume":"11","author":"D Branzei","year":"2010","unstructured":"Branzei, D. & Foiani, M. Maintaining genome stability at the replication fork. Nat. Rev. Mol. Cell Biol. \n                           11, 208\u2013219 (2010).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"221_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ccell.2015.09.015","volume":"28","author":"SX Pfister","year":"2015","unstructured":"Pfister, S. X. et al. Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation. Cancer Cell \n                           28, 557\u2013568 (2015).","journal-title":"Cancer Cell"},{"key":"221_CR26","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.molcel.2015.07.029","volume":"59","author":"R Buisson","year":"2015","unstructured":"Buisson, R., Boisvert, J. L., Benes, C. H. & Zou, L. Distinct but concerted roles of ATR, DNA-PK, and Chk1 in countering replication stress during s phase. Mol. Cell \n                           59, 1011\u20131024 (2015).","journal-title":"Mol. Cell"},{"key":"221_CR27","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.cell.2011.03.044","volume":"145","author":"AC Bester","year":"2011","unstructured":"Bester, A. C. et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell \n                           145, 435\u2013446 (2011).","journal-title":"Cell"},{"key":"221_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.bcp.2015.11.022","volume":"100","author":"M Beyaert","year":"2016","unstructured":"Beyaert, M., Starczewska, E., Van Den Neste, E. & Bontemps, F. A crucial role for ATR in the regulation of deoxycytidine kinase activity. Biochem. Pharmacol. \n                           100, 40\u201350 (2016).","journal-title":"Biochem. Pharmacol."},{"key":"221_CR29","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1021\/bi2001032","volume":"50","author":"S Hazra","year":"2011","unstructured":"Hazra, S., Szewczak, A., Ort, S., Konrad, M. & Lavie, A. Post-translational phosphorylation of serine 74 of human deoxycytidine kinase favors the enzyme adopting the open conformation making it competent for nucleoside binding and release. Biochemistry. \n                           50, 2870\u20132880 (2011).","journal-title":"Biochemistry."},{"key":"221_CR30","doi-asserted-by":"publisher","first-page":"4887","DOI":"10.1074\/jbc.M512129200","volume":"281","author":"C Smal","year":"2006","unstructured":"Smal, C. et al. Identification of in vivo phosphorylation sites on human deoxycytidine kinase. Role of Ser-74 in the control of enzyme activity. J. Biol. Chem. \n                           281, 4887\u20134893 (2006).","journal-title":"J. Biol. Chem."},{"key":"221_CR31","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1182\/blood-2010-08-301267","volume":"117","author":"N Boulos","year":"2011","unstructured":"Boulos, N. et al. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. \n                           117, 3585\u20133595 (2011).","journal-title":"Blood."},{"key":"221_CR32","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/leu.2015.168","volume":"29","author":"TP Hughes","year":"2015","unstructured":"Hughes, T. P. et al. BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia \n                           29, 1832\u20131838 (2015).","journal-title":"Leukemia"},{"key":"221_CR33","doi-asserted-by":"publisher","first-page":"6688","DOI":"10.1073\/pnas.0602030103","volume":"103","author":"RT Williams","year":"2006","unstructured":"Williams, R. T., Roussel, M. F. & Sherr, C. J. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA \n                           103, 6688\u20136693 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"221_CR34","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1158\/1078-0432.CCR-09-1029","volume":"16","author":"Y Dai","year":"2010","unstructured":"Dai, Y. & Grant, S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin. Cancer Res. \n                           16, 376\u2013383 (2010).","journal-title":"Clin. Cancer Res."},{"key":"221_CR35","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/cddis.2012.181","volume":"3","author":"E Fokas","year":"2012","unstructured":"Fokas, E. et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. \n                           3, e441 (2012).","journal-title":"Cell Death Dis."},{"key":"221_CR36","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","volume":"3","author":"DW Fry","year":"2004","unstructured":"Fry, D. W. et al. Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. \n                           3, 1427\u20131438 (2004).","journal-title":"Mol. Cancer Ther."},{"key":"221_CR37","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1021\/jm049354h","volume":"48","author":"PL Toogood","year":"2005","unstructured":"Toogood, P. L. et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4\/6. J. Med. Chem. \n                           48, 2388\u20132406 (2005).","journal-title":"J. Med. Chem."},{"key":"221_CR38","doi-asserted-by":"publisher","first-page":"9480","DOI":"10.1021\/jm501124j","volume":"57","author":"J Nomme","year":"2014","unstructured":"Nomme, J. et al. Structure-guided development of deoxycytidine kinase inhibitors with nanomolar affinity and improved metabolic stability. J. Med. Chem. \n                           57, 9480\u20139494 (2014).","journal-title":"J. Med. Chem."},{"key":"221_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.1985.tb27090.x","volume":"451","author":"ER Giblett","year":"1985","unstructured":"Giblett, E. R. ADA and PNP deficiencies: how it all began. Ann. N. Y. Acad. Sci. \n                           451, 1\u20138 (1985).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"221_CR40","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.celrep.2013.10.027","volume":"5","author":"JK Eykelenboom","year":"2013","unstructured":"Eykelenboom, J. K. et al. ATR activates the S-M checkpoint during unperturbed growth to ensure sufficient replication prior to mitotic onset. Cell Rep. \n                           5, 1095\u20131107 (2013).","journal-title":"Cell Rep."},{"key":"221_CR41","doi-asserted-by":"publisher","first-page":"e1003643","DOI":"10.1371\/journal.pgen.1003643","volume":"9","author":"S Koundrioukoff","year":"2013","unstructured":"Koundrioukoff, S. et al. Stepwise activation of the ATR signaling pathway upon increasing replication stress impacts fragile site integrity. PLoS Genet. \n                           9, e1003643 (2013).","journal-title":"PLoS Genet."},{"key":"221_CR42","doi-asserted-by":"publisher","first-page":"28071","DOI":"10.1074\/jbc.M401574200","volume":"279","author":"K Marheineke","year":"2004","unstructured":"Marheineke, K. & Hyrien, O. Control of replication origin density and firing time in Xenopus egg extracts: role of a caffeine-sensitive, ATR-dependent checkpoint. J. Biol. Chem. \n                           279, 28071\u201328081 (2004).","journal-title":"J. Biol. Chem."},{"key":"221_CR43","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/ncb1145","volume":"6","author":"D Shechter","year":"2004","unstructured":"Shechter, D., Costanzo, V. & Gautier, J. ATR and ATM regulate the timing of DNA replication origin firing. Nat. Cell Biol. \n                           6, 648\u2013655 (2004).","journal-title":"Nat. Cell Biol."},{"key":"221_CR44","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.cell.2012.03.043","volume":"149","author":"V D\u2019Angiolella","year":"2012","unstructured":"D\u2019Angiolella, V. et al. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell \n                           149, 1023\u20131034 (2012).","journal-title":"Cell"},{"key":"221_CR45","doi-asserted-by":"publisher","first-page":"18085","DOI":"10.1074\/jbc.M109.003020","volume":"284","author":"YW Zhang","year":"2009","unstructured":"Zhang, Y. W., Jones, T. L., Martin, S. E., Caplen, N. J. & Pommier, Y. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response. J. Biol. Chem. \n                           284, 18085\u201318095 (2009).","journal-title":"J. Biol. Chem."},{"key":"221_CR46","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/0006-2952(94)90105-8","volume":"48","author":"JG Cory","year":"1994","unstructured":"Cory, J. G. et al. Inhibitors of ribonucleotide reductase. comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. Biochem. Pharmacol. \n                           48, 335\u2013344 (1994).","journal-title":"Biochem. Pharmacol."},{"key":"221_CR47","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1021\/jm9600454","volume":"39","author":"MC Liu","year":"1996","unstructured":"Liu, M. C., Lin, T. S., Cory, J. G., Cory, A. H. & Sartorelli, A. C. Synthesis and biological activity of 3- and 5-amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone. J. Med. Chem. \n                           39, 2586\u20132593 (1996).","journal-title":"J. Med. Chem."},{"key":"221_CR48","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1074\/jbc.M303952200","volume":"279","author":"A Koc","year":"2004","unstructured":"Koc, A., Wheeler, L. J., Mathews, C. K. & Merrill, G. F. Hydroxyurea arrests DNA replication by a mechanism that preserves basal dNTP pools. J. Biol. Chem. \n                           279, 223\u2013230 (2004).","journal-title":"J. Biol. Chem."},{"key":"221_CR49","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/01.cco.0000142071.22226.d2","volume":"16","author":"CR Chitambar","year":"2004","unstructured":"Chitambar, C. R. Gallium compounds as antineoplastic agents. Curr. Opin. Oncol. \n                           16, 547\u2013552 (2004).","journal-title":"Curr. Opin. Oncol."},{"key":"221_CR50","first-page":"580","volume":"55","author":"DW Kufe","year":"1980","unstructured":"Kufe, D. W. et al. High-dose thymidine infusions in patients with leukemia and lymphoma. Blood \n                           55, 580\u2013589 (1980).","journal-title":"Blood"},{"key":"221_CR51","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","volume":"155","author":"LI Toledo","year":"2013","unstructured":"Toledo, L. I. et al. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell \n                           155, 1088\u20131103 (2013).","journal-title":"Cell"},{"key":"221_CR52","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/cyto.a.20458","volume":"71","author":"RS Grigoryan","year":"2007","unstructured":"Grigoryan, R. S., Yang, B., Keshelava, N., Barnhart, J. R. & Reynolds, C. P. Flow cytometry analysis of single-strand DNA damage in neuroblastoma cell lines using the F7-26 monoclonal antibody. Cytometry A \n                           71, 951\u2013960 (2007).","journal-title":"Cytometry A"},{"key":"221_CR53","doi-asserted-by":"publisher","first-page":"L998","DOI":"10.1152\/ajplung.00004.2008","volume":"294","author":"A Kulkarni","year":"2008","unstructured":"Kulkarni, A. & Das, K. C. Differential roles of ATR and ATM in p53, Chk1, and histone H2AX phosphorylation in response to hyperoxia: ATR-dependent ATM activation. Am. J. Physiol. Lung Cell. Mol. Physiol. \n                           294, L998\u2013L1006 (2008).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"221_CR54","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1038\/emboj.2013.211","volume":"32","author":"HW Mankouri","year":"2013","unstructured":"Mankouri, H. W., Huttner, D. & Hickson, I. D. How unfinished business from S-phase affects mitosis and beyond. EMBO J. \n                           32, 2661\u20132671 (2013).","journal-title":"EMBO J."},{"key":"221_CR55","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.molcel.2016.03.006","volume":"62","author":"S Ruiz","year":"2016","unstructured":"Ruiz, S. et al. A genome-wide CRISPR screen identifies CDC25A as a determinant of sensitivity to ATR inhibitors. Mol. Cell \n                           62, 307\u2013313 (2016).","journal-title":"Mol. Cell"},{"key":"221_CR56","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz, M. et al. Dasatinib in imatinib-resistant philadelphia chromosome-positive leukemias. N. Engl. J. Med. \n                           354, 2531\u20132541 (2006).","journal-title":"N. Engl. J. Med."},{"key":"221_CR57","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1139\/o84-077","volume":"62","author":"A Cohen","year":"1984","unstructured":"Cohen, A., Barankiewicz, J., Lederman, H. M. & Gelfand, E. W. Purine metabolism in human T lymphocytes: role of the purine nucleoside cycle. Can. J. Biochem. Cell Biol. \n                           62, 577\u2013583 (1984).","journal-title":"Can. J. Biochem. Cell Biol."},{"key":"221_CR58","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1158\/1535-7163.MCT-15-0982","volume":"15","author":"DR Laks","year":"2016","unstructured":"Laks, D. R. et al. Inhibition of nucleotide synthesis targets brain tumor stem cells in a subset of glioblastoma. Mol. Cancer Ther. \n                           15, 1271\u20131278 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"221_CR59","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1073\/pnas.1524212113","volume":"113","author":"W Kim","year":"2016","unstructured":"Kim, W. et al. [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity. Proc. Natl Acad. Sci. USA \n                           113, 4027\u20134032 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"221_CR60","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nm1724","volume":"14","author":"CG Radu","year":"2008","unstructured":"Radu, C. G. et al. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2\u2032-deoxycytidine analog. Nat. Med. \n                           14, 783\u2013788 (2008).","journal-title":"Nat. Med."},{"key":"221_CR61","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/3337","volume":"4","author":"AF Shields","year":"1998","unstructured":"Shields, A. F. et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med. \n                           4, 1334\u20131336 (1998).","journal-title":"Nat. Med."},{"key":"221_CR62","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.tem.2015.09.013","volume":"26","author":"SJ Humphrey","year":"2015","unstructured":"Humphrey, S. J., James, D. E. & Mann, M. Protein phosphorylation: a major switch mechanism for metabolic regulation. Trends Endocrinol. Metab. \n                           26, 676\u2013687 (2015).","journal-title":"Trends Endocrinol. Metab."},{"key":"221_CR63","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1074\/mcp.M700120-MCP200","volume":"6","author":"L-Y Tang","year":"2007","unstructured":"Tang, L.-Y. et al. Quantitative phosphoproteome profiling of Wnt3a-mediated signaling network indicating the involvement of ribonucleoside-diphosphate reductase M2 subunit phosphorylation at residue serine 20 in canonical Wnt signal transduction. Mol. Cell. Proteomics \n                           6, 1952\u20131967 (2007).","journal-title":"Mol. Cell. Proteomics"},{"key":"221_CR64","doi-asserted-by":"publisher","first-page":"e104125","DOI":"10.1371\/journal.pone.0104125","volume":"9","author":"YL Bunimovich","year":"2014","unstructured":"Bunimovich, Y. L. et al. Deoxycytidine kinase augments ATM-Mediated DNA repair and contributes to radiation resistance. PLoS ONE. \n                           9, e104125 (2014).","journal-title":"PLoS ONE."},{"key":"221_CR65","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ctrv.2013.03.002","volume":"40","author":"E Fokas","year":"2014","unstructured":"Fokas, E. et al. Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treat. Rev. \n                           40, 109\u2013117 (2014).","journal-title":"Cancer Treat. Rev."},{"key":"221_CR66","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1021\/jm301859s","volume":"56","author":"KM Foote","year":"2013","unstructured":"Foote, K. M. et al. Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J. Med. Chem. \n                           56, 2125\u20132138 (2013).","journal-title":"J. Med. Chem."},{"key":"221_CR67","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nchembio.573","volume":"7","author":"PM Reaper","year":"2011","unstructured":"Reaper, P. M. et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. \n                           7, 428\u2013430 (2011).","journal-title":"Nat. Chem. Biol."},{"key":"221_CR68","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1101\/gad.14.6.690","volume":"14","author":"PO Humbert","year":"2000","unstructured":"Humbert, P. O. et al. E2f3 is critical for normal cellular proliferation. Genes Dev. \n                           14, 690\u2013703 (2000).","journal-title":"Genes Dev."},{"key":"221_CR69","doi-asserted-by":"publisher","first-page":"4684","DOI":"10.1128\/MCB.21.14.4684-4699.2001","volume":"21","author":"S Ishida","year":"2001","unstructured":"Ishida, S. et al. Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol. Cell. Biol. \n                           21, 4684\u20134699 (2001).","journal-title":"Mol. Cell. Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-00221-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-00221-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-00221-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T19:45:04Z","timestamp":1671738304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-00221-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,14]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["221"],"URL":"https:\/\/doi.org\/10.1038\/s41467-017-00221-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,14]]},"assertion":[{"value":"20 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing financial interest(s): C.G.R. and J.C. are co-founders of Trethera Corporation. They and the University of California hold equity in Trethera Corporation. The University of California has patented additional intellectual property for small molecule dCK inhibitors invented by C.G.R., J.C., S.P. and T.M.L. This intellectual property has been licensed by Trethera Corporation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"241"}}